Active, Not Recruiting
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients - CA209-743
Updated: 19 November, 2018 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Males and Females at least 18 years of age - Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery - ECOG Performance status of 0 or 1 - Available tumor sample for testing - Acceptable blood work Exclusion Criteria: - Primitive peritoneal, pericardial and tunica vaginalis testis mesotheliomas - Prior chemotherapy for pleural mesothelioma - Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 oranti-CTLA-4 antibody - History of other malignancy unless the subject has been disease-free for at least 3 years - Active, untreated central nervous system (CNS) metastasis Other protocol defined inclusion/exclusion criteria could apply
